As of close of business last night, Krystal Biotech Inc’s stock clocked out at $159.47, down -2.21% from its previous closing price of $163.08. In other words, the price has decreased by -$3.61 from its previous closing price. On the day, 506730 shares were traded.
Ratios:
To gain a deeper understanding of KRYS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.55 and its Current Ratio is at 17.76. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Buy rating and assigned the stock a target price of $160.
On October 24, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $100.
On October 12, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $160.Citigroup initiated its Buy rating on October 12, 2023, with a $160 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 26 when ROMANO KATHRYN sold 8,087 shares for $136.91 per share. The transaction valued at 1,107,180 led to the insider holds 12,556 shares of the business.
Romano Kathryn sold 2,500 shares of KRYS for $325,000 on Jan 22. The Chief Accounting Officer now owns 12,556 shares after completing the transaction at $130.00 per share. On Dec 11, another insider, Krishnan Suma, who serves as the President, R&D of the company, sold 25,000 shares for $105.67 each. As a result, the insider received 2,641,663 and left with 1,574,206 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KRYS now has a Market Capitalization of 4.61B and an Enterprise Value of 4.09B. As of this moment, Krystal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1793.81, and their Forward P/E ratio for the next fiscal year is 32.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 88.98 while its Price-to-Book (P/B) ratio in mrq is 5.78. Its current Enterprise Value per Revenue stands at 80.67 whereas that against EBITDA is 228.43.
Stock Price History:
Over the past 52 weeks, KRYS has reached a high of $173.00, while it has fallen to a 52-week low of $70.51. The 50-Day Moving Average of the stock is 121.87, while the 200-Day Moving Average is calculated to be 117.47.
Shares Statistics:
It appears that KRYS traded 354.28K shares on average per day over the past three months and 630.45k shares per day over the past ten days. A total of 28.24M shares are outstanding, with a floating share count of 23.57M. Insiders hold about 16.70% of the company’s shares, while institutions hold 84.30% stake in the company. Shares short for KRYS as of Feb 15, 2024 were 2.47M with a Short Ratio of 6.97, compared to 1.97M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.75% and a Short% of Float of 10.18%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0.3 and a low estimate of -$0.29, while EPS last year was -$1.76. The consensus estimate for the next quarter is $0.21, with high estimates of $0.65 and low estimates of -$0.22.
Analysts are recommending an EPS of between $3.84 and -$2.96 for the fiscal current year, implying an average EPS of $0.78. EPS for the following year is $4.14, with 6 analysts recommending between $6.77 and $1.49.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for KRYS’s current fiscal year. The highest revenue estimate was $315.4M, while the lowest revenue estimate was $103M, resulting in an average revenue estimate of $237.43M. In the same quarter a year ago, actual revenue was $50.7M, up 368.30% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $416.31M in the next fiscal year. The high estimate is $575M and the low estimate is $251M. The average revenue growth estimate for next year is up 75.30% from the average revenue estimate for this year.
